Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas

Anticancer Research

Volumn 17, Issue 2B, 1997, Pages 1319-1330

  Bodey, Bela ^a,f   Bodey Jr , Bela ^a   Gröger, Angela M ^b   Luck, James V ^c   Siegel, Stuart E ^d   Taylor, Clive R ^a   Kaiser, Hans E ^b,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF VIENNA   (Austria)

^c JOINT REPLACEMENT INSTITUTE   (United States)

^d CHILDREN S HOSPITAL LOS ANGELES   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f NONE   (United States)

Author keywords

Avian erythroblastosis virus oncogene v erbB; c erbB 2 HER 2 neu oncogene and its protein product; c erbB 3 HER 3 oncogene and its receptor; Epidermal growth factor receptor (EGFR); erbB receptor family; Human ontogenesis; Organogenesis

Indexed keywords

ALKALINE PHOSPHATASE; BIOTIN; NEU DIFFERENTIATION FACTOR; ONCOPROTEIN; RECEPTOR SUBUNIT; STREPTAVIDIN;

ANTIGEN ANTIBODY REACTION; ANTIGEN DETECTION; ARTICLE; BREAST CARCINOMA; BREAST METASTASIS; CANCER CELL; CELL CLONE; CELL MEMBRANE; CONTROLLED STUDY; CYTOPLASM; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; IMMUNOREACTIVITY; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RNA TRANSLATION; SIGNAL TRANSDUCTION; SKIN METASTASIS;

BREAST NEOPLASMS; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; NEUREGULINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3;

EID: 0030942007     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Vogelstein B, Kinzler KW: The multistep nature of cancer. Trends Genet 9: 138-141, 1993.
2. Issing WJ, Liebich C, Wustrow TPU, Ullrich A: Coexpression of epidermal growth factor receptor and TGF-α and survival in upper aerodigestive tract cancer. Anticancer Res 16: 283-2887 1996.
3. Volm M, Efferth T, Mattern J: Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations. Anticancer Res 12: 11-20, 1992.
4. Sainsbury JRC, Farndorn JR, Needham GK, Malcolm AJ, Harris AL: Epidermal-growthfactor receptor status as predictor of early recurrence of and death from breast cancer. Lancet 1 (8547): 1398-1402, 1987.
5. Ozawa S, Ueda M, Ando N, Shimizu N, Abe O: Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas. Cancer 63: 2169-2173, 1989.
6. Gullick WJ: A comparison of the structure of single polypeptide chain growth factor receptors that possess protein tyrosine kinase activity. In: Hormones and their actions. Part II (Cooke BA, King RJB, and van der Molen HJ, eds). Amsterdam, Elsevier, pp 349-359, 1988.
7. Fantl WJ, Johnson DE, Williams LT: Signalling by receptor tyrosine kinases. Annu Rev Biochem 62: 453 181, 1993.
8. Temin HM: Studies on carcinogenesis by avian sarcoma viruses. 3. The differential effect of serum and polyanions on multiplication of uninfected and converted cells. J Natl Cancer Inst 37: 167-175, 1966.
9. Spom MB, Todaro GJ: Autocrine secretion and malignant transformation of cells. N Engl J Med 303: 878-880, 1980.
10. Sporn MB, Roberts AB: Autocrine growth factors and cancer. Nature 313: 747-751, 1985.
11. Carpenter G, Cohen S: Epidermal growth factor. Ann Rev Biochem 48: 193-216, 1979.
12. Gregory H: Isolation and structure of urogastrone and its relationship to epidermal growth factor. Nature 257: 325-327, 1975.